Holen Sie sich die Stockscreener-App
52.30
0.08%
-0.04
Handel nachbörslich:
52.30
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Spruce Street Capital LP Purchases New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surpasses Estimates by Over 31%Earnings Growth Analysis - newsline.com
Castleark Management LLC Raises Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA: Record ARCALYST growth, robust pipeline, and key clinical catalysts drive future momentum - TradingView
Kiniksa Pharmaceuticals (KNSA) Edges Lower, Testing Key Support LevelsZero Gamma Level - newsline.com
ESSEX INVESTMENT MANAGEMENT CO LLC's Kiniksa Pharmaceuticals International PLC(KNSA) Holding History - GuruFocus
KNSA Q1 2026 Earnings: EPS Surges Past Estimates, Stock Gains 2.88%Analyst Earnings Estimate - newsline.com
219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA) - Stock Titan
BNP Paribas Financial Markets Has $34.31 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa (KNSA) director receives RSUs and options in equity grants - Stock Titan
Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant - Stock Titan
CEO-linked trust converts 900,000 Kiniksa (NASDAQ: KNSA) Class B shares - Stock Titan
Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares - Stock Titan
Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant - Stock Titan
Kiniksa (KNSA) director exercises RSUs and receives new option grant - Stock Titan
Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards - Stock Titan
Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives - Stock Titan
Kiniksa (KNSA) Q1 2026 Earnings Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plc Files Form 8-K Detailing Annual Meeting Results and Company Information - Minichart
Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates - The Globe and Mail
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41 - GuruFocus
Kiniksa Pharmaceuticals (KNSA) Declines 4.84% as Stock Tests Key Support ZoneSupport Level Bounce - The Legal Advocate
Kiniksa (NASDAQ: KNSA) investors approve board, PwC auditor roles and pay - Stock Titan
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Kiniksa Pharmaceuticals Q1 2026 Earnings: EPS Surprises by 31.5% Despite Stock DeclineRevenue Breakdown Analysis - newsline.com
Kiniksa Pharmaceuticals Files 8-K Disclosing Waiver of Share Conversion Rights with Baker Brothers Life Sciences 9 - Minichart
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights - TipRanks
Baker Bros sets 49.9% voting cap in Kiniksa (NASDAQ: KNSA) - Stock Titan
Kiniksa (NASDAQ: KNSA) sets 49.9% voting cap for Baker Bros. conversions - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Holds Near Flat as Stock Consolidates Near Key LevelsBullish Pattern Stocks - The Legal Advocate
UBS Group AG Purchases 28,099 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Raises Revenue Guidance After Strong ARCALYST Growth - HarianBasis.co
Kiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53 - MSN
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
KNSA Q1 2026 Earnings: Strong EPS Beat Driven by Operational Efficiency and Product GrowthEarnings Power Value - thelegaladvocate.com
Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighStill a Buy? - MarketBeat
How Kiniksa (KNSA) builds value over time (Institutional Demand) 2026-05-11Chaikin Flow - newsline.com
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International : 2025 Annual Report - marketscreener.com
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA) - Stock Titan
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):